Cipla Accused Of Promoting Generic For Unauthorized Use
This article was originally published in PharmAsia News
Executive Summary
India's drug controller general has asked Cipla to repond to a distributor's charge Cipla falsely promoted a cancer drug, the generic Erlocip (erlotinib hydrochloride). Distributor Taksal Pharma carries Roche Scientific products such as its Tarceva, of which Erlocip is a generic. The distributor complained Cipla promotional literature suggests using Erlocip to treat four kinds of cancers, when the branded version has been approved in India only for non small-cell lung cancer and pancreatic cancer, and the generic only for the former. (Click here for more